Search Results - "KISH, Julie A"

Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck by Cooper, Jay S., MD, Zhang, Qiang, PhD, Pajak, Thomas F., PhD, Forastiere, Arlene A., MD, Jacobs, John, MD, Saxman, Scott B., MD, Kish, Julie A., MD, Kim, Harold E., MD, Cmelak, Anthony J., MD, Rotman, Marvin, MD, Lustig, Robert, MD, Ensley, John F., MD, Thorstad, Wade, MD, Schultz, Christopher J., MD, Yom, Sue S., MD, Ang, K. Kian, MD, PhD

“…Purpose Previous analysis of this Intergroup trial demonstrated that with a median follow-up among surviving patients of 45.9 months, the concurrent…”
Get full text

The Older Adult With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: Knowledge Gaps and Future Direction in Assessment and Treatment by Maggiore, Ronald, MD, Zumsteg, Zachary S., MD, BrintzenhofeSzoc, Karlynn, PhD, MSW, Trevino, Kelly M., PhD, Gajra, Ajeet, MD, Korc-Grodzicki, Beatriz, MD, PhD, Epstein, Joel B., DMD, MSD, Bond, Stewart M., PhD, RN, AOCN, Parker, Ira, DDS, MA, MPH, Kish, Julie A., MD, Murphy, Barbara A., MD, VanderWalde, Noam A., MD

“…Older adults with head and neck squamous cell carcinoma (HNSCC) pose unique treatment and supportive care challenges to oncologists and other cancer care…”
Get full text

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck by Cooper, Jay S, Pajak, Thomas F, Forastiere, Arlene A, Jacobs, John, Campbell, Bruce H, Saxman, Scott B, Kish, Julie A, Kim, Harold E, Cmelak, Anthony J, Rotman, Marvin, Machtay, Mitchell, Ensley, John F, Chao, K.S. Clifford, Schultz, Christopher J, Lee, Nancy, Fu, Karen K

“…In this randomized trial of the postoperative treatment of high-risk squamous-cell carcinoma of the head and neck, concurrent radiotherapy plus chemotherapy…”
Get full text

An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer by ADELSTEIN, David J, YI LI, ADAMS, George L, WAGNER, Henry JR, KISH, Julie A, ENSLEY, John F, SCHULLER, David E, FORASTIERE, Arlene A

“…The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable…”
Get full text

Patient choice for high‐volume center radiation impacts head and neck cancer outcome by Naghavi, Arash O., Echevarria, Michelle I., Strom, Tobin J., Abuodeh, Yazan A., Venkat, Puja S., Ahmed, Kamran A., Demetriou, Stephanie, Frakes, Jessica M., Kim, Youngchul, Kish, Julie A., Russell, Jeffery S., Otto, Kristen J., Chung, Christine H., Harrison, Louis B., Trotti, Andy, Caudell, Jimmy J.

“…Background Studies suggest treatment outcomes may vary between high (HVC)‐ and low‐volume centers (LVC). Radiation therapy (RT) for head and neck cancer (HNC)…”
Get full text

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) by Ma, Brigette B Y, Lim, Wan-Teck, Goh, Boon-Cher, Hui, Edwin P, Lo, Kwok-Wai, Pettinger, Adam, Foster, Nathan R, Riess, Jonathan W, Agulnik, Mark, Chang, Alex Y C, Chopra, Akhil, Kish, Julie A, Chung, Christine H, Adkins, Douglas R, Cullen, Kevin J, Gitlitz, Barbara J, Lim, Dean W, To, Ka-Fai, Chan, K C Allen, Lo, Y M Dennis, King, Ann D, Erlichman, Charles, Yin, Jun, Costello, Brian A, Chan, Anthony T C

“…Purpose This multinational study evaluated the antitumor activity of nivolumab in nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were…”
Get full text

Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma by Chung, Christine H, Li, Jiannong, Steuer, Conor E, Bhateja, Priyanka, Johnson, Matthew, Masannat, Jude, Poole, Maria I, Song, Feifei, Hernandez-Prera, Juan C, Molina, Helen, Wenig, Bruce M, Kumar, Sunil, Kuperwasser, Charlotte, Stephens, Philip J, Farinhas, Joaquim M, Shin, Dong M, Kish, Julie A, Muzaffar, Jameel, Kirtane, Kedar, Rocco, James W, Schell, Michael J, Saba, Nabil F, Bonomi, Marcelo

“…A phase II multi-institutional clinical trial was conducted to determine overall survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck…”
Get full text

Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck by Tanvetyanon, Tawee, Padhya, Tapan, McCaffrey, Judith, Kish, Julie A., Deconti, Ronald C., Trotti, Andy, Rao, Nikhil G.

“…Background Despite resection followed by adjuvant radiotherapy, high‐risk cutaneous squamous cell carcinomas of the head and neck region (SCCHN) often recur…”
Get full text

Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer by Rao, Nikhil G., Han, Gang, Greene, John N., Tanvetyanon, Tawee, Kish, Julie A., De Conti, Ronald C., Chuong, Michael D., Shridhar, Ravi, Biagioli, Matthew C., Caudell, Jimmy J., Trotti, Andy M.

“…Radiation therapy (RT) or chemoradiation therapy (CRT) for carcinoma of the head and neck can result in high rates of candidiasis and mucositis. Prophylactic…”
Get full text

Patient‐reported outcomes in immunotherapy for head and neck cancer by Kirtane, Kedar, Hoogland, Aasha I., Li, Xiaoyin, Rodriguez, Yvelise, Scheel, Kelsey, Small, Brent J., Oswald, Laura B., Muzaffar, Jameel, Kish, Julie A., Bonomi, Marcelo, Bhateja, Priyanka, Saba, Nabil F., Steuer, Conor E., Chung, Christine H., Jim, Heather S. L.

“…Background Data about patient‐reported outcomes (PROs) among patients with head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint…”
Get full text

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study by Chung, Christine H, Bonomi, Marcelo, Steuer, Conor E, Li, Jiannong, Bhateja, Priyanka, Johnson, Matthew, Masannat, Jude, Song, Feifei, Hernandez-Prera, Juan C, Wenig, Bruce M, Molina, Helen, Farinhas, Joaquim M, McMullen, Caitlin P, Wadsworth, J Trad, Patel, Krupal B, Kish, Julie A, Muzaffar, Jameel, Kirtane, Kedar, Rocco, James W, Schell, Michael J, Saba, Nabil F

“…We hypothesized the combination of cetuximab and nivolumab would improve survival in recurrent and/or metastatic (R/M) HNSCC by providing synergy in cancer…”
Get full text

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors by GRAY, Jhanelle E, HAURA, Eric, TETTEH, Leticia, AKAR, Angela, XIUHUA ZHAO, SCHELL, Michael J, BEPLER, Gerold, ALTIOK, Soner, CHIAPPORI, Alberto, TANVETYANON, Tawee, WILLIAMS, Charles C, PINDER-SCHENCK, Mary, KISH, Julie A, KREAHLING, Jenny, LUSH, Richard, NEUGER, Anthony

“…Panobinostat, a histone deacetylase (HDAC) inhibitor, enhances antiproliferative activity in non-small cell lung cancer (NSCLC) cell lines when combined with…”
Get full text

Determining optimal follow‐up in the management of human papillomavirus‐positive oropharyngeal cancer by Frakes, Jessica M., Naghavi, Arash O., Demetriou, Stephanie K., Strom, Tobin J., Russell, Jeffery S., Kish, Julie A., McCaffrey, Judith C., Otto, Kristen J., Padhya, Tapan A., Harrison, Louis B., Trotti, Andy M., Caudell, Jimmy J.

“…BACKGROUND Determining the optimal follow‐up for patients can help maximize the use of health care resources. This is particularly true in a growing epidemic…”
Get full text

The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/− systemic therapy in locally advanced head and neck cancer by Kish, Julie A., Zhang, Qiang, Langer, Corey J., Nguyen-Tân, Phuc Felix, Rosenthal, David I., Weber, Randal S., List, Marcy A., Wong, Stuart J., Garden, Adam S., Hu, Kenneth, Trotti, Andy M., Bonner, James A., Jones, Christopher U., Yom, Sue S., Thorstad, Wade, Schultz, Christopher J., Ridge, John A., Shenouda, George, Harris, Jonathan, Le, Quynh-Thu

“…To examine the role age plays in the treatment and prognosis of locally advanced head and neck cancer (LAHNC) treated definitively with radiation alone or…”
Get full text

Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥ 70 years by Strom, Tobin J, Naghavi, Arash O, Trotti, Andy M, Russell, Jeffery, Kish, Julie A, McCaffrey, Judith, Otto, Kristen J, Harrison, Louis B, Caudell, Jimmy J

“…Abstract Purpose Concurrent chemoradiotherapy (CRT) is the standard of care for many sites of locally advanced head and neck squamous cell carcinomas (LAHNC)…”
Get full text

Using Big Data in oncology to prospectively impact clinical patient care: A proof of concept study by Dougoud-Chauvin, Vérène, Lee, Jae Jin, Santos, Edgardo, Williams, Vonetta L., Battisti, Nicolò M.L., Ghia, Kavita, Sehovic, Marina, Croft, Cortlin, Kim, Jongphil, Balducci, Lodovico, Kish, Julie A., Extermann, Martine

“…Big Data is widely seen as a major opportunity for progress in the practice of personalized medicine, attracting the attention from medical societies and…”
Get full text

A Phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149) by Swinnen, Lode J., Rankin, Cathryn, Carraway, Hetty, Albain, Kathy S., Townsend, Jeannette J., Budd, George Thomas, Kish, Julie A., Rivkin, Saul E., Blumenthal, Deborah T.

“…Inhibition of DNA excision repair can modulate resistance to cisplatin. Cytosine arabinoside (Ara-C) and hydroxyurea (HU), in combination, inhibit the…”
Get full text

The treatment challenge of hormone-refractory prostate cancer by Kish, J A, Bukkapatnam, R, Palazzo, F

“…Both the demographics and treatment of hormone-refractory prostate cancer (HRPC) are changing. Patients are younger and healthier, with fewer comorbidities…”
Get more information

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial by Mell, Loren K, Torres-Saavedra, Pedro A, Wong, Stuart J, Kish, Julie A, Chang, Steven S, Jordan, Richard C, Liu, Tian, Truong, Minh Tam, Winquist, Eric W, Takiar, Vinita, Wise-Draper, Trisha, Robbins, Jared R, Rodriguez, Cristina P, Awan, Musaddiq J, Beadle, Beth M, Henson, Christina, Narayan, Samir, Spencer, Sharon A, Powell, Steven, Dunlap, Neal, Sacco, Assuntina G, Hu, Kenneth Shung, Park, Henry S, Bauman, Julie E, Harris, Jonathan, Yom, Sue S, Le, Quynh-Thu

“…Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. We aimed…”
Get full text

Abstract 5751: Patient-reported toxicities in head and neck cancer patients treated with immunotherapy by James, Brian W., Hoogland, Aasha I., Irizarry-Arroyo, Nathaly, Muzaffar, Jameel, Kirtane, Kedar, Kish, Julie A., Jim, Heather S., Chung, Christine H.

“…Abstract Background: Immune checkpoint inhibitors (ICIs) (i.e. nivolumab, pembrolizumab) are FDA-approved agents used in the treatment of various head and neck…”
Get full text